Codex DNA, Inc. (DNAY) News
Filter DNAY News Items
DNAY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DNAY News From Around the Web
Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate DNAY as an investment opportunity.
Telesis Bio, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportAs you might know, Telesis Bio, Inc. ( NASDAQ:DNAY ) just kicked off its latest third-quarter results with some very... |
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue EstimatesCodex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Telesis Bio Inc. Reports Third Quarter 2022 Financial Results-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. |
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live |
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrumentAgreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp® Digital-to-Biological Converter™ (DBC) instrument for full |
Codex DNA Announces Plan to Change Corporate Name to Telesis BioNovel name reflects expansion of capabilities and solutionsSAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio. “Our innovative and pioneering spirit, and the versatility and power of our technologies, have enabled us to expand our portfolio to include an array of tools for both synthetic biology and genomics applications. To reflect the expa |
Codex DNA Expands Application of Proprietary Error Correction TechnologyNew BioXp® Error Corrected Libraries have two-fold increase in sequence fidelitySAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp® Error-corrected Libraries kits that enable researchers to automate synthesis of DNA variant libraries on the award-winning BioXp® automated synthetic biology workstation. “This addition to the BioXp® solutions demonstrates a new and expand |
Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, NetherlandsBioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – nominated for prestigious World of Laboratory Tech AwardSAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at the World of Technology & Science conference which begins tomorrow in Utrecht, Netherlands. The BioXp™ 9600 system will be showcased at the |
Codex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationBioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – empowers scientists to accelerate discovery of new vaccines and biologicsSAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of the BioXp™ 9600 system, a next-generation high throughput platform designed to revolutionize synthetic biology workflows. T |
Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for Codex DNA (DNAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |